Michael A. Savage

631 total citations
16 papers, 514 citations indexed

About

Michael A. Savage is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Pharmacology. According to data from OpenAlex, Michael A. Savage has authored 16 papers receiving a total of 514 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Cellular and Molecular Neuroscience and 4 papers in Pharmacology. Recurrent topics in Michael A. Savage's work include Pharmacological Receptor Mechanisms and Effects (6 papers), Neuropeptides and Animal Physiology (5 papers) and Inflammatory mediators and NSAID effects (3 papers). Michael A. Savage is often cited by papers focused on Pharmacological Receptor Mechanisms and Effects (6 papers), Neuropeptides and Animal Physiology (5 papers) and Inflammatory mediators and NSAID effects (3 papers). Michael A. Savage collaborates with scholars based in United States, China and Canada. Michael A. Savage's co-authors include Awilda Stapelfeld, E. Ann Hallinan, Melvin Reichman, Timothy J. Hagen, Donna L. Hammond, Henry I. Mosberg, Ronald C. Haaseth, Nizal S. Chandrakumar, Chafiq Moummi and Thomas H. Lanthorn and has published in prestigious journals such as The Journal of Comparative Neurology, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Michael A. Savage

15 papers receiving 495 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael A. Savage United States 12 248 183 165 94 67 16 514
Etsuo Ohshima Japan 16 192 0.8× 106 0.6× 98 0.6× 68 0.7× 106 1.6× 30 547
Chun Wel Lin United States 13 183 0.7× 123 0.7× 178 1.1× 70 0.7× 57 0.9× 25 567
Marsha A. McLaughlin United States 19 304 1.2× 120 0.7× 156 0.9× 78 0.8× 47 0.7× 31 833
Andrew S. Felts United States 20 447 1.8× 385 2.1× 222 1.3× 101 1.1× 28 0.4× 35 796
Michèle Rizzolio United States 12 181 0.7× 69 0.4× 117 0.7× 104 1.1× 93 1.4× 22 616
Larry P. Bausher United States 11 211 0.9× 106 0.6× 141 0.9× 31 0.3× 72 1.1× 21 515
Craig Polson United States 11 193 0.8× 122 0.7× 172 1.0× 147 1.6× 210 3.1× 17 595
John P. Felix United States 20 751 3.0× 256 1.4× 167 1.0× 84 0.9× 97 1.4× 30 915
Daryl S. Walter United Kingdom 16 217 0.9× 50 0.3× 367 2.2× 107 1.1× 126 1.9× 39 736
M. S. NOBBS United Kingdom 10 312 1.3× 237 1.3× 181 1.1× 40 0.4× 50 0.7× 21 598

Countries citing papers authored by Michael A. Savage

Since Specialization
Citations

This map shows the geographic impact of Michael A. Savage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Savage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Savage more than expected).

Fields of papers citing papers by Michael A. Savage

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Savage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Savage. The network helps show where Michael A. Savage may publish in the future.

Co-authorship network of co-authors of Michael A. Savage

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Savage. A scholar is included among the top collaborators of Michael A. Savage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Savage. Michael A. Savage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Kondratov, Oleksandr, Liudmyla Kondratova, Ronald J. Mandel, et al.. (2021). A comprehensive study of a 29-capsid AAV library in a non-human primate central nervous system. Molecular Therapy. 29(9). 2806–2820. 39 indexed citations
2.
Erskine, Daniel, Alan Thomas, John‐Paul Taylor, et al.. (2017). Neuronal Loss and Α-Synuclein Pathology in the Superior Colliculus and Its Relationship to Visual Hallucinations in Dementia with Lewy Bodies. American Journal of Geriatric Psychiatry. 25(6). 595–604. 26 indexed citations
3.
Savage, Michael A., Richard McQuade, & Alexander Thiele. (2017). Segregated fronto‐cortical and midbrain connections in the mouse and their relation to approach and avoidance orienting behaviors. The Journal of Comparative Neurology. 525(8). 1980–1999. 18 indexed citations
4.
Hallinan, E. Ann, et al.. (2001). 2,4-Disubstituted oxazoles and thiazoles as latent pharmacophores for diacylhydrazine of SC-51089, a potent PGE2 antagonist. Bioorganic & Medicinal Chemistry. 9(1). 1–6. 42 indexed citations
5.
Savage, Michael A. & Stewart Page. (2000). Business and Arts Students. Journal of College Student Psychotherapy. 14(4). 43–55.
6.
Hallinan, E. Ann, et al.. (1996). Aminoacetyl Moiety as a Potential Surrogate for Diacylhydrazine Group of SC-51089, a Potent PGE2 Antagonist, and Its Analogs. Journal of Medicinal Chemistry. 39(2). 609–613. 57 indexed citations
7.
Hammond, Donna L., et al.. (1994). Antinociception produced by oral, subcutaneous or intrathecal administration of SC-39566, an opioid dipeptide arylalkylamide, in the rodent.. Journal of Pharmacology and Experimental Therapeutics. 268(2). 607–615. 6 indexed citations
9.
Hallinan, E. Ann, Awilda Stapelfeld, Michael A. Savage, & Melvin Reichman. (1994). 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid,2-[3-[2-(furanylmethyl)thio]-1-oxopropyl]hydrazide (SC-51322): A potent PGE2 antagonist and analgesic. Bioorganic & Medicinal Chemistry Letters. 4(3). 509–514. 63 indexed citations
11.
Savage, Michael A., et al.. (1993). SC-46275: A potent and highly selective agonist at the EP3 receptor. Prostaglandins Leukotrienes and Essential Fatty Acids. 49(6). 939–943. 28 indexed citations
12.
Hallinan, E. Ann, Timothy J. Hagen, Michael Rafferty, et al.. (1993). N-Substituted dibenzoxazepines as analgesic PGE2 antagonists. Journal of Medicinal Chemistry. 36(22). 3293–3299. 63 indexed citations
13.
Stapelfeld, Awilda, Michael A. Savage, Melvin Reichman, et al.. (1992). Systemic analgesic activity and .delta.-opioid selectivity in [2,6-dimethyl-Tyr1, D-Pen2, D-Pen5]enkephalin. Journal of Medicinal Chemistry. 35(4). 684–687. 83 indexed citations
14.
Chandrakumar, Nizal S., et al.. (1992). Preparation and opioid activity of analogs of the analgesic dipeptide 2,6-dimethyl-L-tyrosyl-N-(3-phenylpropyl)-D-alaninamide. Journal of Medicinal Chemistry. 35(2). 223–233. 31 indexed citations
15.
Chandrakumar, Nizal S., Awilda Stapelfeld, Patrick M. Beardsley, et al.. (1992). Analogs of the .delta. opioid receptor selective cyclic peptide [cyclic][2-D-penicillamine,5-D-penicillamine]-enkephalin: 2',6'-dimethyltyrosine and Gly3-Phe4 amide bond isostere substitutions. Journal of Medicinal Chemistry. 35(16). 2928–2938. 31 indexed citations
16.
Savage, Michael A.. (1992). The socialization of business and arts students: Epistemological and value changes between disciplines.. Scholarship at UWindsor (University of Windsor). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026